Products

European brown hare syndrome virus cDNA and Antigen

Cat#

Product Name

Swiss Prot#

Size

Price (US$)

Order

PN0400

Recombinant Protein-European brown hare syndrome virus Major capsid protein (a.a.25 to 576)

Q96727

100 µg

1195

Order

PN0401

Recombinant Protein-European brown hare syndrome virus Protein p16 (a.a.31 to 138)

Q96725

100 µg

1195

Order

PN0402

Recombinant Protein-European brown hare syndrome virus Protein p23 (a.a.139 to 334)

Q96725

100 µg

1195

Order

PN0403

Recombinant Protein-European brown hare syndrome virus Precursor p41 (a.a.712 to 1108)

Q96725

100 µg

1195

Order

PN0404

Recombinant Protein-European brown hare syndrome virus Protein p29 (a.a.712 to 986)

Q96725

100 µg

1195

Order

PN0405

Recombinant Protein-European brown hare syndrome virus Protein p18 (a.a.930 to 1101)

Q96725

100 µg

1195

Order

PN0406

Recombinant Protein-European brown hare syndrome virus Viral genome-linked protein (a.a.987 to 1101)

Q96725

100 µg

1195

Order

PN0407

Recombinant Protein-European brown hare syndrome virus Capsid protein VP60 (a.a.2000 to 2334)

Q96725

100 µg

1195

Order

RPN0400

cDNA-European brown hare syndrome virus Major capsid protein (a.a.25 to 576)

Q96727

2 µg

2755

Order

RPN0401

cDNA-European brown hare syndrome virus Protein p16 (a.a.31 to 138)

Q96725

2 µg

535

Order

RPN0402

cDNA-European brown hare syndrome virus Protein p23 (a.a.139 to 334)

Q96725

2 µg

975

Order

RPN0403

cDNA-European brown hare syndrome virus Precursor p41 (a.a.712 to 1108)

Q96725

2 µg

1980

Order

RPN0404

cDNA-European brown hare syndrome virus Protein p29 (a.a.712 to 986)

Q96725

2 µg

1370

Order

RPN0405

cDNA-European brown hare syndrome virus Protein p18 (a.a.930 to 1101)

Q96725

2 µg

855

Order

RPN0406

cDNA-European brown hare syndrome virus Viral genome-linked protein (a.a.987 to 1101)

Q96725

2 µg

800

Order

RPN0407

cDNA-European brown hare syndrome virus Capsid protein VP60 (a.a.2000 to 2334)

Q96725

2 µg

1670

Order

RPN0398

cDNA-Equine infectious anemia virus Envelope protein (a.a.21 to 361)

Q9WK03

2 µg

1700

Order

RPN0399

cDNA-Equine infectious anemia virus Envelope glycoprotein (a.a.7 to 444)

P22427

2 µg

2185

Order

European brown hare syndrome virus cDNA and recombinant antigen

  • Codon-optimized cDNA is cloned into E. coli expression vector with 6x His-tag at N-terminus and ready-to-use for recombinant protein production.
  • Recombinant protein applications: Western Blot may be used for other applications determined by the user.
  • Protein Purity: >90%, as determined by SDS-PAGE under reducing conditions.
  • Protein Activity: N/A
  • Protein Tag:  Contains A 6x histidine tag at N-terminus.
  • Protein Formulation: Liquid
  • Source: Produced from E. coli

European brown hare syndrome (EBHS) virus is a virus that causes a highly contagious and often fatal disease of European hares. The disease was first identified in Europe in the 1980s and has since caused significant declines in hare populations. The virus is a member of the Caliciviridae family and is closely related to rabbit hemorrhagic disease virus (RHDV) which causes a similar disease in rabbits.
The EBHS virus can infect both wild and domestic hares, and is spread through contact with infected animals, their urine, feces, or saliva, or through contact with contaminated objects such as feed or clothing. The clinical signs of the disease include fever, respiratory distress, and hemorrhages in internal organs. Mortality can reach up to 100% in infected hares.

EBHSV is a single-stranded, positive-sense RNA virus, with a genome of approximately 7.5 kilobases in size. The EBHSV genome encodes for a polyprotein that is cleaved into four structural proteins (VP1-VP4) and three non-structural proteins (2Apro, 2B, 2C). The virus replication takes place in the cytoplasm of infected cells, and the virus is shed in the saliva, urine, and feces of infected animals, which makes the disease easily transmissible.

European brown hare syndrome (EBHS) virus antigen refers to a specific protein or component of the EBHS virus that can stimulate an immune response in animals. Antigens are used in the development of diagnostic tests and vaccines as they allow the detection or protection against the virus. Some of the key EBHS proteins include:

The EBHSV virion is composed of several structural proteins, including:

Major capsid protein – the main protein that forms the outer shell of the virion and protects the viral RNA.

p16 – a non-structural protein that is involved in viral replication.

p23 – another non-structural protein that is involved in viral replication.

p41 – a structural protein that forms the protrusions on the surface of the virion.

p29 – a structural protein that is involved in virion assembly and maturation.

p18 – a structural protein that forms the smaller protrusions on the surface of the virion.

Viral genome-linked protein – a protein that is covalently linked to the viral RNA and is involved in viral replication.

VP60 – a major structural protein that forms the capsid of the virion.

These structural proteins work together to allow the virus to infect and replicate within host cells. The VP60 protein is particularly important for the virus to evade the host immune system, as it can rapidly mutate and change its antigenic structure. The complexity of the EBHSV virion and the variability of its structural proteins make it a challenging target for the development of effective vaccines and antiviral therapies.

Understanding the functions and interactions of these proteins is critical for developing effective treatments and prevention strategies for EBHSV-associated diseases. Ongoing research is focused on uncovering more about the virus and its proteins, with the goal of ultimately finding a way to control and eradicate the disease.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.

 

Welcome to BitClone

Magnetic Beads Make Things Simple